All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On Monday 3rd April during this year's American Association for Cancer Research (AACR) annual meeting, a poster (2770 / 2) by Ian McConnell, from VCU Massey Cancer Center, Richmond, VA, et al. titled “Bcl-2 overexpression is a predictive biomarker for the combination of ABT-199 with chemotherapy in diffuse large B-cell lymphoma cell lines” was presented.
The group hypothesized that BCL-2 overexpression correlates with sensitivity to ABT-199 plus chemotherapy in DLBCL. To test this, they analyzed the effect of ABT-199 in four different DLBCL cell lines with different levels of BCL-2 expression: (from highest to lowest) CARNAVAL, OCI-ly18, SU-DHL-4, and SU-DHL-8.
The poster was concluded by stating that these preclinical results support the use of BCL-2 overexpression as a predictive biomarker, enabling more accurate selection of DLBCL patients who are likely to benefit from combining ABT-199 with chemotherapy.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox